

ENROLMENT FORM



TELEPHONE: 1-844-MAP-PAM2 (1-844-627-7262) FAX: 1-844-922-0242 EMAIL: MAPinfo@innomar-strategies.com

PATIENT INFORMATION				
Patient's name:	Date of birth:		Gender: F 🗆 M 🗅	
Parent/guardian name:	Last name	d d / m m / y y		
Address:				
Home phone:	Leave messages: Y	N Preferred time to call:	AM 🗆 PM 🖵 Evening 🗅	
Other phone:	Leave messages: Y C	☐ N ☐ Preferred time to call:	AM 🗆 PM 🗅 Evening 🗅	
PHYSICIAN INFORMATION				
Physician's name:	Specialty:	Li	cense number:	
Email:	Address:		Postal Code:	
Key contact/admin:	Telephone:	Telephone: Fax:		
Nurse:	Telephone: Fax:		ax:	
PRESCRIPTION				
KANUMA® (sebelipase alfa) (Refer to monograph for experient's body weight:kg Dosage: □ 1 mg/kg of body weight administer infusion every 2 weeks □ 1 mg/kg of body weight administer infusion every 1 week □ 3 mg/kg of body weight administer infusion every 1 week	complete prescribing informa	Directions/special instructions: Physician signature:		
□ Other Repeats:		Date:		
PATIENT AUTHORIZATION AND CONSEN	г			
☐ Patient consented verbally				
I understand that the MAP TM patient support program is Program on behalf of Alexion for the purpose of assistin providers may be appointed by Alexion to administer M described on the next page of this Enrolment Form.	ng Canadian patients wit	th obtaining access to medical treat	tment. I understand that other service	
Signature of patient/legal representative:				
Date signed:				

SEE FULL PATIENT CONSENT TERMS ON THE NEXT PAGE OF THIS ENROLMENT FORM. PLEASE ENSURE YOU HAVE FULLY READ AND UNDERSTAND THE PATIENT CONSENT TERMS.

MAP™ is the treatment support program for patients. MAP provides information, education, and assistance.

By signing this Authorization and Consent, you (or your representative) agree that information that may identify you that is provided to MAPTM by you and/or (1) your physician(s) and other healthcare providers involved in the treatment of your medical condition ("Providers"); (2) the distributor, pharmacy, infusion clinic, or home health agency that supplies or dispenses your medical therapy ("Distributor"); and (3) your health insurer, payor, or patient assistance program ("Payor") (collectively, "Personal Information") will be used to manage and administer MAP, including provision of MAP services to you as further described below. For these purposes you agree that the Providers, Distributor, and Payor may disclose Personal Information to Alexion Pharma Canada, including, but not limited to, its employees, affiliates, sub-contractors, agents, and other representatives (together, "Alexion"). You understand that your participation in MAP is also subject to Alexion's Privacy Notice, available at https://alexion.com/Legal#privacy, which provides you with additional information about Alexion's privacy practices and the privacy rights that may be available to you.

The Personal Information collected, used, or disclosed as part of your participation in MAP may include name, address, other contact information, date of birth, diagnoses, medical reports, orders, prescriptions, records, medical histories, findings, prognoses, plans of care and discharge summaries, billing information, insurance claims, utilization review reports, survey responses, and other information you provide in connection with your MAP participation. Your Personal Information may be used or disclosed for the following purposes:

Coordination of Care: Between you or your representative, the Provider, Distributor, or Payor for the coordination of your medical care, including therapy adherence reminders.

Disease Management/Patient Education: To provide information, training, and case management services to you or your representative, or any Provider, Distributor, or Payor.

Clinical Research/Treatment Protocols/Meetings: To inform and refer you or your representative of clinical research studies, treatment protocols, disease-related surveys, or meetings that may be of interest to you.

Reviewing Your Insurance Coverage/Funding Options: To review, verify, and assist you or your representative in understanding the medications and services that your Payor covers, if you ask and request such service. This may include review of your personal financial information to determine if you qualify for financial assistance which may be available under MAP. If you do not qualify for insurance or other coverage to pay for your treatment, your Personal Information and other information may be used to determine if you might qualify in the future for such coverage or to help you identify other sources of payment or financial support.

Billing and Payment: To coordinate the preparation, filing, and processing of health insurance claims, the evaluation of coding (billing) issues, and the resolution or collection of any payment due to Provider, Distributor, Payor or Alexion for your treatment.

Distribution of Therapy: To coordinate the distribution of the medical product to you.

Product Orders: To fulfill medical product orders, answer any questions that you or your representative may have and to inform you about other services that may be of interest to you.

Government Agencies: To provide information as required or requested by representatives of government agencies, review boards, and others who watch over the safety of drugs (or operations) of pharmaceutical manufacturers. Alexion has a legal obligation to report adverse drug events to various local and international health authorities and to monitor product complaints. Personal Information provided to MAP may be (i) monitored by Alexion for safety related data in order to ensure compliance with these legal reporting requirements and (ii) reported to local or international health authorities. Alexion may contact you or your physician for additional information to fulfill its reporting obligations.

Other Use of Information: To provide you with other MAP services that may be in place from time to time, such as a buddy or mentorship program, or otherwise use or disclose your Personal Information with your consent.

Alexion may also remove identifiers from your Personal Information, or combine your Personal Information with the information of others who participate in MAP to create aggregated data, and use such data to improve and refine MAP and to design and implement other patient programs. Alexion may also use such information for analytics, reporting, and research purposes, including strategy development and the identification of trends such as product utilization, adherence, or outcomes.

Transfer and Processing of Personal Information: To transfer the Personal Information, including between provinces or outside of Canada, for the purposes of communicating the information to Alexion's parent and affiliated entities, and/or for the purposes of storing and processing the information on behalf of Alexion in relation to MAP. Your Authorization and Consent serves as explicit consent that your data can be transferred and processed in countries outside Canada, which may not ensure the same level of data protection as provided in Canada, to provide you with the information you requested. The Personal Information will be protected while outside of Canada; however, to the extent required under applicable law, your Personal Information may be accessed by the courts, law enforcement and national security authorities of that other country.

If another service provider is appointed by Alexion to administer MAP, your Personal Information will be transferred to this service provider to ensure the continuity of the MAP services.

This Authorization and Consent may be revoked by you at any time. Please note that if you revoke this Authorization and Consent, your ability to receive MAP services may be limited. To revoke your consent, update or access your Personal Information, express a privacy-related concern, or inquire about the privacy practices of MAP, you may contact the Alexion Canada Privacy Officer at 3100 Rutherford Road, Suite 300, Vaughan, Ontario L4K 0G6 or by email at privacy@alexion.com.

KANUMA® (sebelipase alfa) indication

KANUMA® (sebelipase alfa), indicated for the treatment of infants, children and adults diagnosed with lysosomal acid lipase (LAL) deficiency, has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit.



